- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07584798
Self-Monitoring OCT
September 15, 2026 updated by: Warren Sobol, Case Western Reserve University
Self-Monitoring Optical Coherence Tomography Device for Retinal Telehealth
The purpose of this research study is to test participants ability to obtain OCT images of the eyes using an OCT device that is comparable to FDA-approved OCT devices on the market, without the help of an eye technician.
Patients with ocular diseases often need to come to frequent appointments with an eye care provider for close monitoring and evaluation.
Transportation difficulties, other medical problems, and limited appointments slots can make regular follow-up challenging.
In addition, the anxiety of permanent vision loss and subjective nature of monitoring symptoms highlight the need for an alternative solution in which patients can self-generate OCT images of the eye for the eye care provider to review.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
Principal Investigator:
- Warren Sobol, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 1. Provision of signed and dated informed consent.
- 2. Age ≥ 18 years.
- 3. Presenting for care at a University Hospitals Eye Institute clinic
- 4. Willing to complete study questionnaires.
- 5. Scheduled to undergo standard technician-acquired OCT
Exclusion Criteria:
- 1. Unable to provide informed consent or, in the judgment of study staff, unable to understand study procedures.
- 2. Unable to cooperate with imaging or maintain stable positioning such that an evaluable OCT scan cannot be obtained (e.g., severe tremor or inability to maintain head position).
- 3. Facial skin condition or open wound at the points of device contact that would make use of the headrest unsafe.
- 4. Acute medical or ocular condition requiring immediate evaluation that, in the PI's judgment, precludes participation at that time.
- 5. Any other condition that, in the opinion of the PI/designee, would place the participant at undue risk or compromise data quality (documented).
- 6. Patients with visual acuity <20/200.
- 7. Patients with significant media opacities precluding an OCT scan (posterior subcapsular cataract, vitreous hemorrhage, etc), or severe ptosis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Self-administered OCT Images
Participants will use an OCT device to obtain OCT images of the eyes.
|
Self-administered OCT imaging using modified portable OCT with headrest and software workflow to enable patient self-operation and secure image transfer to a remote reading center.
|
|
Active Comparator: Technician-acquired OCT
Technicians will use a standard OCT device to obtain OCT images of the eyes as per standard of care.
|
Technician-acquired OCT obtained using routine clinical equipment during the same visit
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of inner retinal abnormalities detected as measured by OCT images
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Number of outer retinal abnormalities detected as measured by OCT images.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Sensitivity as measured by OCT images.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Specificity as measured by OCT images.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Positive predictive value (PPV) as measured by OCT images.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Negative predictive value (NPV) as measured by OCT images.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Image-quality as recorded by nurse coordinator during patient interaction with the device.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Number of successful completion of self-scans as recorded by nurse coordinator during patient interaction with the device.
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
|
Number of repeated attempts
Time Frame: through study completion, an average of 1 year
|
through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Warren Sobol, MD, University Hospitals Cleveland Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
September 1, 2026
Primary Completion (Estimated)
December 15, 2027
Study Completion (Estimated)
December 15, 2027
Study Registration Dates
First Submitted
May 7, 2026
First Submitted That Met QC Criteria
May 7, 2026
First Posted (Actual)
May 13, 2026
Study Record Updates
Last Update Posted (Actual)
September 17, 2026
Last Update Submitted That Met QC Criteria
September 15, 2026
Last Verified
September 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- STUDY20211004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.